List of 113 Retooled Measures

NQF #:	0001
MEASURE TITLE:	Asthma Assessment
MEASURE DESCRIPTION:	Percentage of patients aged 5 through 40 years with a diagnosis of asthma who were
	evaluated during at least one office visit within 12 months for the frequency (numeric) of
	daytime and nocturnal asthma symptoms.
	0002
NQF #: MEASURE TITLE:	0002 Appropriate Testing for Children with Pharyngitis
MEASURE DESCRIPTION:	The percentage of children 2-18 years of age who were diagnosed with Pharyngitis,
	dispensed an antibiotic and received a group A streptococcus (strep) test for the
	episode.
NQF #:	0004
MEASURE TITLE:	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a)
MEASURE DESCRIPTION:	Initiation, (b) Engagement The percentage of adolescent and adult patients with a new episode of alcohol and
MEASONE DESCRIPTION.	other drug (AOD) dependence who initiate treatment through an inpatient AOD
	admission, outpatient visit, intensive outpatient encounter or partial hospitalization within
	14 days of the diagnosis and who initiated treatment and who had two or more
	additional services with an AOD diagnosis within 30 days of the initial visit.
	0040
NQF #: MEASURE TITLE:	0012 Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
MEASURE DESCRIPTION:	Percentage of patients, regardless of age, who gave birth during a 12-month period who
	were screened for HIV infection during the first or second prenatal visit.
NQF #:	0013
MEASURE TITLE:	Hypertension: Blood Pressure Measurement
MEASURE DESCRIPTION:	Percentage of patient visits for patients aged 18 years and older with a diagnosis of
	hypertension with blood pressure (BP) recorded.
NQF #:	0014
MEASURE TITLE:	Prenatal Care: Anti-D Immune Globulin
MEASURE DESCRIPTION:	Percentage of D(Rh) negative, unsensitized patients, regardless of age, who gave birth
	during a 12-month period who received anti-D immune globulin at 26-30 weeks
	gestation.
NQF #:	0018
MEASURE TITLE:	Controlling High Blood Pressure
MEASURE DESCRIPTION:	The percentage of patients 18-85 years of age who had a diagnosis of hypertension and
	whose BP was adequately controlled during the measurement year.
	0022
MEASURE TITLE:	Drugs to be avoided in the elderly: a. Patients who receive at least one drug to be avoided, b. Patients who receive at least two different drugs to be avoided
MEASURE DESCRIPTION:	Percentage of patients ages 65 years and older who received at least one drug to be
	avoided in the elderly in the measurement year. Percentage of patients 65 years of age
	and older who received at least two different drugs to be avoided in the elderly in the
	measurement year.
NQF #:	0024 Weight Assessment and Counseling for Children and Adelescents
MEASURE TITLE: MEASURE DESCRIPTION:	Weight Assessment and Counseling for Children and Adolescents The percentage of patients 2-17 years of age who had an outpatient visit with a PCP or
	OB/GYN and who had evidence of BMI percentile documentation, counseling for
	nutrition and counseling for physical activity during the measurement year.

NQF #:	0027
MEASURE TITLE:	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers
	and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation
	Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were current smokers or
	tobacco users, who were seen by a practitioner during the measurement year and who
	received advice to quit smoking or tobacco use or whose practitioner recommended or
	discussed smoking or tobacco use cessation medications, methods or strategies.
NQF #:	0028a
MEASURE TITLE:	Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment
MEASURE DESCRIPTION:	Percentage of patients aged 18 years or older who have been seen for at least 2 office
	visits, who were queried about tobacco use one or more times within 24 months.
NQF #:	0028b
MEASURE TITLE:	Preventive Care and Screening Measure Pair: b. Tobacco Cessation Intervention
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older identified as tobacco users within the
	past 24 months and have been seen for at least 2 office visits, who received cessation
	intervention.
	0004
NQF #:	0031 Recent Concer Servering
MEASURE TITLE:	Breast Cancer Screening
MEASURE DESCRIPTION:	The percentage of women 40-69 years of age who had a mammogram to screen for
	breast cancer.
NQF #:	0032
MEASURE TITLE:	Cervical Cancer Screening
MEASURE DESCRIPTION:	The percentage of women 21-63 years of age who received one or more Pap tests to
	screen for cervical cancer.
NQF #:	0033
MEASURE TITLE:	Chlamydia Screening for Women
MEASURE DESCRIPTION:	The percentage of women 15-24 years of age who were identified as sexually active
	and who had at least one test for chlamydia during the measurement year.
NQF #:	0034
MEASURE TITLE:	Colorectal Cancer Screening
MEASURE DESCRIPTION:	The percentage of adults 50-75 years of age who had appropriate screening for
	colorectal cancer.
	0000
	0036
MEASURE TITLE:	Use of Appropriate Medications for Asthma
MEASURE DESCRIPTION:	The percentage of patients 5-50 years of age during the measurement year who were identified as having persistent asthma and were appropriately prescribed medication
	during the measurement year.
	during the measurement year.
NQF #:	0038
MEASURE TITLE:	Childhood immunization Status
MEASURE DESCRIPTION:	The percentage of children 2 years of age who had four diphtheria, tetanus and acellular
	pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); two H
	influenza type B (HIB); three hepatitis B (Hep B), one chicken pox (VZV); four
	pneumococcal conjugate (PCV); two hepatitis A (Hep A); two or three rotavirus (RV);
	and two influenza (flu) vaccines by their second birthday. The percentage of children 2
	years of age who had the complete series of vaccines by 2 years of age. There are 12
	rates calculated for this measure 10 for the individual immunizations and 2 for the series
	of immunizations.

NQF #:	0041
MEASURE TITLE:	Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years
	Old
MEASURE DESCRIPTION:	Percentage of patients aged 50 years and older who received an influenza
	immunization during the flu season (September through February).
NQF #:	0043
MEASURE TITLE:	Pneumonia Vaccination Status for Older Adults
MEASURE DESCRIPTION:	The percentage of patients 65 years of age and older who have ever received a
	pneumococcal vaccine.
NQF #:	0045
MEASURE TITLE:	Osteoporosis: Communication with the Physician Managing Ongoing Care Post-
	Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and
	Older
MEASURE DESCRIPTION:	Percentage of patients aged 50 years and older treated for a hip, spine, or distal radial
	fracture with documentation of communication with the physician managing the
	patient's on-going care that a fracture occurred and that the patient was or should
	be tested or treated for osteoporosis.
	0040
	0046
MEASURE TITLE:	Osteoporosis: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
MEASURE DESCRIPTION:	Percentage of female patients aged 65 years and older who have a central dual-energy
	X-ray absorptiometry measurement ordered or performed at least once since age 60 or
	pharmacologic therapy prescribed within 12 months.
NQF #:	0047
MEASURE TITLE:	Asthma Pharmacologic Therapy
MEASURE DESCRIPTION:	Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or
MEASURE DESCRIPTION:	severe persistent asthma who were prescribed either the preferred long-term control
MEASURE DESCRIPTION:	
	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment.
NQF #:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048
	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older
NQF #:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal
NQF #: MEASURE TITLE:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or
NQF #: MEASURE TITLE:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal
NQF #: MEASURE TITLE: MEASURE DESCRIPTION:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed.
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049
NQF #: MEASURE TITLE: MEASURE DESCRIPTION:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months.
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months. 0051 Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the-
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months. 0051 Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the- counter (OTC) medications
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months. 0051 Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the- counter (OTC) medications Percentage of patient visits for patients aged 21 years and older with a diagnosis of OA
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months. 0051 Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the- counter (OTC) medications
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months. 0051 Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the- counter (OTC) medications Percentage of patient visits for patients aged 21 years and older with a diagnosis of OA with an assessment for use of anti-inflammatory or analgesic OTC medications.
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months. 0051 Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the- counter (OTC) medications Percentage of patient visits for patients aged 21 years and older with a diagnosis of OA with an assessment for use of anti-inflammatory or analgesic OTC medications. 0052
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months. 0051 Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the- counter (OTC) medications Percentage of patient visits for patients aged 21 years and older with a diagnosis of OA with an assessment for use of anti-inflammatory or analgesic OTC medications. 0052 Low Back Pain: Use of Imaging Studies
NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. 0048 Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years or older with fracture of the hip, spine or distal radius that had a central dual-energy X-ray absorptiometry measurement ordered or performed or pharmacologic therapy prescribed. 0049 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy within 12 months. 0051 Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the- counter (OTC) medications Percentage of patient visits for patients aged 21 years and older with a diagnosis of OA with an assessment for use of anti-inflammatory or analgesic OTC medications. 0052

NQF #:	0055
MEASURE TITLE:	Diabetes: Eye Exam
MEASURE DESCRIPTION:	The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had
	a retinal or dilated eye exam or a negative retinal exam (no evidence of retinopathy) by
	an eye care professional.
NQF #:	0056
MEASURE TITLE:	Diabetes: Foot Exam
MEASURE DESCRIPTION:	The percentage of patients aged 18-75 years with diabetes (type 1 or type 2) who had a
	foot exam (visual inspection, sensory exam with monofilament, or pulse exam).
NQF #:	0059
MEASURE TITLE:	Diabetes: HbA1c Poor Control
MEASURE DESCRIPTION:	The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had
MEASORE DESCRIPTION.	HbA1c > 9.0% .
	10/10 > 3.0%.
NQF #:	0060
MEASURE TITLE:	Hemoglobin A1c Test for Pediatric Patients
MEASURE DESCRIPTION:	Percentage of pediatric patients with diabetes with a HBA1c test in a 12-month
	measurement period.
NQF #:	0061
MEASURE TITLE:	Diabetes: Blood Pressure Management
MEASURE DESCRIPTION:	The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had
	BP < 140/90 mmHg.
NQF #:	0062
MEASURE TITLE:	Diabetes: Urine Screening
MEASURE DESCRIPTION:	The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had
	a nephropathy screening test or evidence of nephropathy.
NQF #:	0064
MEASURE TITLE:	Diabetes: LDL Management & Control
MEASURE DESCRIPTION:	The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had
	LDL-C <100mg/dL.
NQF #:	0066
MEASURE TITLE:	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor
	or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and
	Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of CAD who also have
	diabetes and/or left ventricular systolic dysfunction (LVSD) who were prescribed ACE
	Inhibitor or ARB therapy.
NQF #:	0067
MEASURE TITLE:	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients
MEASORE IIIEE.	with CAD
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of CAD who were
	prescribed oral antiplatelet therapy.
NQF #:	0068
MEASURE TITLE:	Ischemic Vascular Disease (IVD): Use of Aspirin or another Antithrombotic
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were discharged alive for
	acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous
	transluminal coronary angioplasty (PTCA) from January 1 - November 1 of the year
	transluminal coronary angioplasty (PTCA) from January 1 - November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease
	transluminal coronary angioplasty (PTCA) from January 1 - November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and
	transluminal coronary angioplasty (PTCA) from January 1 - November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease

NQF #:	0069
MEASURE TITLE:	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of
	Inappropriate Use
MEASURE DESCRIPTION:	Percentage of children who were given a diagnosis of URI and were not dispensed an
	antibiotic prescription on or three days after the episode date.
NQF #:	0070
MEASURE TITLE:	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior
MEASORE IIILE.	Myocardial Infarction (MI)
	Percentage of patients aged 18 years and older with a diagnosis of CAD and prior MI
MEASURE DESCRIPTION:	
	who were prescribed beta-blocker therapy.
	0070
NQF #:	0073
MEASURE TITLE:	Ischemic Vascular Disease (IVD): Blood Pressure Management
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were discharged alive for
	acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous
	transluminal coronary angioplasty (PTCA) from January 1-November 1 of the year prior
	to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD)
	during the measurement year and the year prior to the measurement year and whose
	most recent blood pressure is in control (<140/90 mmHg).
NQF #:	0074
MEASURE TITLE:	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of CAD who were
	prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines).
NQF #:	0075
MEASURE TITLE:	Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were discharged alive for
	acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous
	transluminal coronary angioplasty (PTCA) from January 1- November 1 of the year prior
	to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD)
	during the measurement year and the year prior to the measurement year and who had
	a complete lipid profile performed during the measurement year and whose LDL-C was
	< 100 mg/dL.
NQF #:	0081
MEASURE TITLE:	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or
	Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic
	Dysfunction (LVSD)
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of heart failure and
	LVSD (LVEF < 40%) who were prescribed ACE inhibitor or ARB therapy.
NQF #:	0083
MEASURE TITLE:	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction
MEASORE ITTEL.	(LVSD)
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of heart failure who
MEASURE DESCRIPTION.	also have LVSD (LVEF < 40%) and who were prescribed beta-blocker therapy.
	also have $LVDD$ ($LVLI < 40.00$) and who were prescribed bela-blocker therapy.
NOE #	0084
NQF #: MEASURE TITLE:	
MEASURE TITLE:	Heart Failure (HF) : Warfarin Therapy Patients with Atrial Fibrillation
MEASURE DESCRIPTION:	Percentage of all patients aged 18 and older with a diagnosis of heart failure and
	paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy.
	0000
NQF #:	0086
	0086
MEASURE TITLE:	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
MEASURE TITLE: MEASURE DESCRIPTION:	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation Percentage of patients aged 18 years and older with a diagnosis of POAG who have
	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation Percentage of patients aged 18 years and older with a diagnosis of POAG who have been seen for at least 2 office visits, who have an optic nerve head evaluation during
	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation Percentage of patients aged 18 years and older with a diagnosis of POAG who have

NQF #:	0088
MEASURE TITLE:	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema
	and Level of Severity of Retinopathy
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy
MEASORE DESCRIPTION:	who had a dilated macular or fundus exam performed which included documentation of
	the level of severity of retinopathy and the presence or absence of macular edema
	during one or more office visits within 12 months.
NQF #:	0089
MEASURE TITLE:	Diabetic Retinopathy: Communication with the Physician Managing Ongoing
MEASORE IIIEE.	Diabetes Care
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy
MEASURE DESCRIPTION.	who had a dilated macular or fundus exam performed with documented communication
	to the physician who manages the on-going care of the patient with diabetes mellitus
	regarding the findings of the macular or fundus exam at least once within 12 months.
	regarding the indings of the macular of fundus exam at least once within 12 months.
NQF #:	0097
MEASURE TITLE:	Medication Reconciliation
MEASURE DESCRIPTION:	Percentage of patients aged 65 years and older discharged from any inpatient facility
	(e.g. hospital, skilled nursing facility, or rehabilitation facility) and seen within 60 days
	following discharge in the office by the physician providing on-going care who had a
	reconciliation of the discharge medications with the current medication list in the medical
	record documented.
NQF #:	0102
MEASURE TITLE:	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy
MEASURE DESCRIPTION:	Percentage of symptomatic patients aged 18 years and older with a diagnosis of COPD
	who were prescribed an inabled bronchodilator.
NQF #:	0103
MEASURE TITLE:	Major Depressive Disorder (MDD): Diagnostic Evaluation
MEASURE DESCRIPTION:	Percentage of patients with a diagnosis of major depressive disorder who met the DSM-
	IV™ criteria during the visit in which the new diagnosis or recurrent episode was
	identified.
NQF #:	0104
MEASURE TITLE:	Major Depressive Disorder (MDD): Suicide Risk Assessment
MEASURE DESCRIPTION:	Percentage of patients who had a suicide risk assessment completed at each visit.
NQF #:	0105
MEASURE TITLE:	Anti-depressant medication management: (a) Effective Acute Phase Treatment,
	(b)Effective Continuation Phase Treatment
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were diagnosed with a new
	episode of major depression, treated with antidepressant medication, and who remained
	on an antidepressant medication treatment.
NQF #:	0106
MEASURE TITLE:	Diagnosis of attention deficit hyperactivity disorder (ADHD) in primary care for
MEASORE ITTEL.	school age children and adolescents
MEASURE DESCRIPTION:	Percentage of patients newly diagnosed with ADHD whose medical record contains
	documentation of DSM-IV-TR or DSM-PC criteria.
NQF #:	0107
MEASURE TITLE:	Management of attention deficit hyperactivity disorder (ADHD) in primary care for
	school age children and adolescents
MEASURE DESCRIPTION:	Percentage of patients treated psychostimulant with medication for the diagnosis of
	ADHD whose medical record contains documentation of a follow-up visit at least twice a
	year.

NQF #:	0108
MEASURE TITLE:	ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity
	Disorder (ADHD) Medication
MEASURE DESCRIPTION:	a. Initiation Phase: Percentage of children 6 - 12 years of age as of the Index
MEASURE DESCRIPTION.	Prescription Episode Start Date with an ambulatory prescription dispensed for and
	ADHD medication and who had one follow-up visit with a practitioner with prescribing
	authority during the 30-Day Initiation Phase.
	b. Continuation and Maintenance (C&M) Phase: Percentage of children 6 - 12 years of
	age as of the Index Prescription Episode Start Date with an ambulatory prescription
	dispensed for ADHD medication who remained on the medication for at least 210 days
	and who in addition to the visit in the Initiation Phase had at least two additional follow-
	up visits with a practitioner within 270 days (9 months) after the Initiation Phase ends.
NQF #:	0112
MEASURE TITLE:	Bipolar Disorder: Monitoring change in level-of-functioning
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with an initial diagnosis or new
	episode/presentation of bipolar disorder.
NQF #:	0132
MEASURE TITLE:	Aspirin at Arrival
MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients who received aspirin within 24 hours before
	or after hospital arrival.
NQF #:	0137
MEASURE TITLE:	ACEI or ARB for LVSD
MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients with left ventricular systolic dysfunction
MEASURE DESCRIPTION.	(LVSD) who are prescribed an ACEI or ARB at hospital discharge. For purposes of this
	measure, LVSD is defined as chart documentation of a left ventricular ejection fraction
	(LVEF) less than 40% or a narrative description of left ventricular systolic (LVS) function
	consistent with moderate or severe systolic dysfunction.
	0400
NQF #:	0138
MEASURE TITLE:	Urinary catheter-associated urinary tract infection for intensive care unit (ICU)
	patients
MEASURE DESCRIPTION:	Standardized Infection Ration (SIR) of healthcare-associated, catheter-associated
	urinary tract infections (CAUTI) among patients in intensive care units (ICUs), excluding
	patients in neonatal ICUs (NICUs).
NQF #:	0139
MEASURE TITLE:	Central line catheter-associated blood stream infection rate for ICU and high-risk
	nursery (HRN) patients
MEASURE DESCRIPTION:	Standardized Infection Ration (SIR) of healthcare-associated, central line-associated
	bloodstream infections (CLABSI) among patients in intensive care units (ICUs) and
	Neonatal Intensive Care Units (NICUs).
NQF #:	0142
MEASURE TITLE:	Aspirin Prescribed at Discharge
MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital
	discharge.
NQF #:	0147
MEASURE TITLE:	Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in
	Immunocompetent Patients
MEASURE DESCRIPTION:	Immunocompetent patients with Community-Acquired Pneumonia who receive an initial
	antibiotic regimen during the first 24 hours that is consistent with current guidelines.

NQF #:	0148
MEASURE TITLE:	Blood Cultures Performed in the Emergency Department Prior to Initial Antibiotic
	Received in Hospital
MEASURE DESCRIPTION:	Pneumonia patients whose initial emergency room blood culture specimen was
	collected prior to first hospital dose of antibiotics. This measure focuses on the
	treatment provided to Emergency Department patients prior to admission orders.
	······································
NQF #:	0151
MEASURE TITLE:	Initial Antibiotic Received Within 6 Hours of Hospital Arrival
MEASURE DESCRIPTION:	Pneumonia patients who receive their first dose of antibiotics within 6 hours after arrival
	at the hospital.
NQF #:	0160
MEASURE TITLE:	Beta-Blocker Prescribed at Discharge
MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients who are prescribed a beta-blocker at hospital
	discharge.
NQF #:	0163
MEASURE TITLE:	Primary PCI Received Within 90 Minutes of Hospital Arrival
MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the
	ECG closest to arrival time receiving primary PCI during the hospital stay with a time
	from hospital arrival to PCI of 90 minutes or less.
	0404
NQF #: MEASURE TITLE:	0164 Fibringlytic Therepy Received Within 20 Minutes of Heavital Arrival
MEASURE DESCRIPTION:	Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival Acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the
MEASURE DESCRIPTION.	ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and
	having a time from hospital arrival to fibrinolysis of 30 minutes or less.
	naving a time norm nospital arrival to holmolysis of 50 minutes of less.
NQF #:	0239
MEASURE TITLE:	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (when indicated
	in ALL patients)
MEASURE DESCRIPTION:	Patient Age: All patients age 18 years and older Procedures: surgical procedures for
	which VTE prophylaxis is indicated in all patients who had an order for LMWH, LDUH,
	adjusted-dose warfarin, fondaparinux or mechanical prophylaxis given within 24 hours
	prior to incision time or 24 hours after surgery end time.
NQF #:	0241
MEASURE TITLE:	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial
	Fibrillation at Discharge
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal
	atrial fibrillation who were prescribed an anticoagulant at discharge.
	and noniation who were presended an anticoaguiant at discharge.
NQF #:	0246
MEASURE TITLE:	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic
	Resonance Imaging (MRI) Reports
MEASURE DESCRIPTION:	Percentage of final reports for CT or MRI studies of the brain performed either: In the
	hospital within 24 hours of arrival, OR In an outpatient imaging center to confirm initial
	diagnosis of stroke, TIA or intracranial hemmorhage For patients aged 18 years and
	older with either a diagnosis of ischemic stroke or transient ischemic attack (TIA) or
	intracranial hemorrhage OR at least one documented symptom consistent with ischemic
	stroke or TIA or intracranial hemorrhage that includes documentation of the presence or
	absence of each of the following: hemorrhage and mass lesion and acute infarction.
NOE #	0268
NQF #: MEASURE TITLE:	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second
	Generation Cephalosporin
MEASURE DESCRIPTION:	Percentage of surgical patients aged 18 years and older undergoing procedures with
MEASONE DESCRIPTION.	r croentage of surgical patients aged to years and older undergoing procedules with

	the indications for a first OR second generation cephalosporin prophylactic antibiotic who had an order for cefazolin OR cefuroxime for antimicrobial prophylaxis.
NQF #:	0270
MEASURE TITLE:	Perioperative Care: Timing of Prophylactic Antibiotics - Ordering Physician
MEASURE DESCRIPTION:	Percentage of surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic parenteral antibiotics who have an order for an antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required).
NQF #:	0271
MEASURE TITLE:	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)
MEASURE DESCRIPTION:	Percentage of non-cardiac surgical patients aged 18 years and older undergoing
	procedures with the indications for prophylactic antibiotics AND who received a prophylactic antibiotic, who have an order for discontinuation of prophylactic antibiotics within 24 hours of surgical end time.
NQF #:	0298
MEASURE TITLE:	Central Line Bundle Compliance
MEASURE DESCRIPTION:	The percentage of intensive care patients in the included ICUs with central lines for who all five elements of the central line "bundle" are documented on the daily goals sheet, central line checklist, patient"s medical record, or other documentation tool.
NQF #:	0300
MEASURE TITLE:	Cardiac Surgery Patients With Controlled 6 A.M. Postoperative Blood Glucose
MEASURE DESCRIPTION:	Cardiac surgery patients with controlled 6 A.M. blood glucose (less than or equal to 200 mg/dL) on postoperative day one (POD 1) and postoperative day two (POD 2) with Anesthesia End Date being postoperative day zero (POD 0).
NQF #:	0302
MEASURE TITLE:	Ventilator Bundle
MEASURE DESCRIPTION:	The percentage of intensive care patients on mechanical ventilation for whom all five elements of the ventilator "bundle" are implemented and documented.
NQF #:	0321
	En 10(and Daniel Diana (CODD), Diana (Orang (an handle month Danitan and Diahasia
MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis
MEASURE TITLE: MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period.
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period.
	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which
MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients
MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis
MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care.
MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges.
MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges.
MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges.
MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE TITLE: MEASURE TITLE:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment Percentage of PICU patients receiving pain assessment on admission.
MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment Percentage of PICU patients receiving pain assessment on admission. 0342
MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE TITLE: MEASURE TITLE:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a Kt/V>=1.7 OR patients wo havea Kt/V<1.7 with a documented plan of care 3 times a year (every 4 months) during the 12 month reporting period. 0323 End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment Percentage of PICU patients receiving pain assessment on admission.

NQF #:	0348
MEASURE TITLE:	latrogenic Pneumothorax in Non-Neonates (risk adjusted) (PDI5)
MEASURE DESCRIPTION:	Percent of medical and surgical discharges, age under 18 years, with ICD-9-CM code of
	iatrogenic pneumothorax in any secondary diagnosis field.
NQF #:	0356
MEASURE TITLE:	Blood Cultures Performed Within 24 Hours Prior to or 24 Hours After Hospital
	Arrival for Patients Who Were Transferred or Admitted to the ICU Within 24 Hours of Hospital Arrival
MEASURE DESCRIPTION:	Pneumonia patients transferred or admitted to the ICU within 24 hours of hospital
	arrival, who had blood cultures performed within 24 hours prior to or the day prior to
	arrival, the day of arrival, or within 24 hours after arrival to the hospital.
NQF #:	0362
MEASURE TITLE:	Foreign Body left after procedure (PDI3)
MEASURE DESCRIPTION:	Discharges with foreign body accidently left in during procedure per 1000 discharges.
	0005
NQF #: MEASURE TITLE:	0385 Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon
MEASONE DESCRIPTION.	cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy,
	or have previously received adjuvant chemotherapy within the 12-month reporting
	period.
NQF #:	0387
MEASURE TITLE:	Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen
	Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
MEASURE DESCRIPTION:	Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER
	or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.
NQF #:	0389
MEASURE TITLE:	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk
	Prostate Cancer Patients
MEASURE DESCRIPTION:	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk
	of recurrence receiving interstitial prostate brachytherapy, OR external beam
	radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not
	have a bone scan performed at any time since diagnosis of prostate cancer.
NQF #:	0397
MEASURE TITLE:	Hepatitis C: Antiviral Treatment Prescribed
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C
	who were prescribed peginterferon and ribavirin therapy within the 12 month reporting
	period.
NQF #:	
MEASURE TITLE: MEASURE DESCRIPTION:	Hepatitis C: Hepatitis A Vaccination in Patients with HCV
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who have received at least one injection of hepatitis A vaccine, or who have documented
	immunity to hepatitis A.
NQF #:	0400
MEASURE TITLE:	Hepatitis C: Hepatitis B Vaccination in Patients with HCV
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who
	have received at least one injection of hepatitis B vaccine, or who have documented
	have received at least one injection of hepatitis B vaccine, or who have documented immunity to hepatitis B.

NQF #:	0401
MEASURE TITLE:	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who
	were counseled regarding the risks of alcohol consumption at least once within the 12
	month reporting period.
NQF #:	0416
MEASURE TITLE:	Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus
	who were evaluated for proper footwear and sizing.
NQF #:	0421
MEASURE TITLE:	Preventive Care and Screening: Body Mass Index (BMI), Screening and Follow-Up
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a calculated BMI in the past six
	months or during the current visit documented in the medical record AND if the most
	recent BMI is outside parameters, a follow-up plan is documented.
NQF #:	0453
MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2
	(POD 2) with day of surgery being day zero
MEASURE DESCRIPTION:	Surgical patients with urinary catheter removed on Postoperative Day 1 or
	Postoperative Day 2 with day of surgery being day zero.
NQF #:	0471
MEASURE TITLE:	Cesarean Rate for Low-Risk Birth Women
MEASURE DESCRIPTION:	Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term,
	singleton, vertex) identifies the portion of cesarean births that has the most variation
	among practicioners, hospitals, regions and states. Unlike other cesarean measures, it
	focuses attention on the proportion of cesarean births that is affected by elective
	medical practices such as induction and early labor admission. Furthermore, the
	success (or lack thereof) of management of the first labor directly impacts the remainder
	of the woman's reproductive life especially given the current high rate of repeat
	cesarean births. This is also the measure used in Healthy Person 2010 (Objective
	16.9a, US DHS, 2000). and previously recevived endorsement from the American
	College of Obstetricians and Gynecologists (American College of Obstetricians and
	Gynecologists: Task Force on Cesarean Delivery, 2000). A recent European review of
	cesarean birth measures also identified that this measure pinpointed the portion of
	cesarean births that had the greatest variation and contributed the most to the rise in
	overall rates in every country studied (Brennan, 2009).
NQF #:	0484
MEASURE TITLE:	Proportion of Infants 22 to 29 Weeks Gestation Treated with Surfactant who are
	Treated within 2 Hours of Birth
MEASURE DESCRIPTION:	Proportion of infants with gestational age between 22 and 29 completed weeks who were treated with surfactant and were treated within two hours of birth.
	were treated with suffactant and were treated within two hours of birth.
NQF #:	0496
MEASURE TITLE:	Median Time from ED Arrival to ED Departure for Discharged ED Patients
MEASURE DESCRIPTION:	Median time from emergency department arrival to time of departure from the
MEASURE DESCRIPTION.	emergency room for patients discharged from the emergency department.
	energency room for patients discharged from the emergency department.
NQF #:	0507
MEASURE TITLE:	Stenosis Measurement in Carotid Imaging Studies
MEASURE DESCRIPTION:	Percentage of final reports for carotid imaging studies (neck MR angiography [MRA],
	neck CT angiography [CTA], neck duplex ultrasound, carotid angiography [MICA],
	include direct or indirect reference to measurements of distal internal carotid diameter
	as the denominator for stenosis measurement.

NQF #:	0508
MEASURE TITLE:	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in
	Mammography Screening
MEASURE DESCRIPTION:	Percentage of final reports for screening mammograms that are classified as "probably
	benign".
	-
NQF #:	0510
MEASURE TITLE:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy
MEASURE DESCRIPTION:	Percentage of final reports for procedures using fluoroscopy that include documentation
	of radiation exposure or exposure time.
NQF #:	0511
MEASURE TITLE:	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients
	Undergoing Bone Scintigraphy
MEASURE DESCRIPTION:	Percentage of final reports for all patients, regardless of age, undergoing bone
	scintigraphy that include physician documentation of correlation with existing relevant
	imaging studies (eg, x-ray, MRI, CT) that were performed.
NQF #:	0513
MEASURE TITLE:	Use of Contrast: Thorax CT
MEASURE DESCRIPTION:	This measure calculates the percentage of thorax studies that are performed with and
	without contrast out of all thorax studies performed (those with contrast, those without
	contrast, and those with both).
	0540
NQF #:	0519 Disketia Fact Care and Patient/Conscious Education Implemented During Short
MEASURE TITLE:	Diabetic Foot Care and Patient/Caregiver Education Implemented During Short Term Episodes of Care
MEASURE DESCRIPTION:	Percentage of short term home health episodes of care during which diabetic foot care
MEASURE DESCRIPTION.	and education were included in the physician-ordered plan of care and implemented for
	patients with diabetes.
	patients with diabetes.
NQF #:	0527
MEASURE TITLE:	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision
MEASURE DESCRIPTION:	Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical
	incision. Patients who received vancomycin or a fluoroquinolone for prophylactic
	antibiotics should have the antibiotics initiated within two hours prior to surgical incision.
	Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is
	acceptable to start these antibiotics within two hours prior to incision time.
NQF #:	0528
MEASURE TITLE:	Prophylactic Antibiotic Selection for Surgical Patients
MEASURE DESCRIPTION:	Surgical patients who received prophylactic antibiotics consistent with current guidelines
	(specific to each type of surgical procedure).
NQF #:	0529
MEASURE TITLE:	Prophylactic Antibiotics Discontinued Within 24 Hours After Surgery End Time
MEASURE DESCRIPTION:	Surgical patients whose prophylactic antibiotics were discontinued within 24 hours after
	Anesthesia End Time. The Society of Thoracic Surgeons (STS) Practice Guideline for
	Antibiotic Prophylaxis in Cardiac Surgery (2006) indicates that there is no reason to
	extend antibiotics beyond 48 hours for cardiac surgery and very explicitly states that
	antibiotics should not be extended beyond 48 hours even with tubes and drains in place
	for cardiac surgery.
NOE #	0575
NQF #: MEASURE TITLE:	0575 Diabatas: HbA1a Control (28%)
MEASURE DESCRIPTION:	Diabetes: HbA1c Control (<8%) The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had
MEASURE DESCRIPTION:	HbA1c <8.0%.

NQF #:	0608
MEASURE TITLE:	Pregnant women that had HBsAg testing
MEASURE DESCRIPTION:	This measure reports compliance to hepatitis B surface antigen (HBsAg) testing during
	pregnancy; if the HBsAg test is absent, then the exclusion criteria (diagnosis of hepatitis
	B infection) is applied.
NQF #:	ACP-017-10
MEASURE TITLE:	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History
	of Adenomatous Polyps - Avoidance of Inappropriate Use
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior colonic polyp in previous colonoscopy findings who had a follow-
	up interval of 3 or more years since their last colonoscopy documented in the
	colonoscopy report.
NQF #:	OT3-011-10
MEASURE TITLE:	Depression Remission at Twelve Months
MEASURE DESCRIPTION:	Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9
	score > 9 who demonstrate remission at twelve months defined as PHQ-9 score less
	than 5. This measure applies to both patients with newly diagnosed and existing
	depression whose current PHQ-9 score indicates a need for treatment.
NQF #:	OT3-012-10
MEASURE TITLE:	Depression Remission at Six Months
MEASURE DESCRIPTION:	Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9
MEASURE DESCRIPTION.	score > 9 who demonstrate remission at six months defined as PHQ-9 score less than
	5. This measure applies to both patients with newly diagnosed and existing depression
	whose current PHQ-9 score indicates a need for treatment.
NQF #:	OT3-022-10
MEASURE TITLE:	Depression Utilization of the PHQ-9 Tool
MEASURE DESCRIPTION:	Adult patients age 18 and older with the diagnosis of major depression or dysthymia
	who have a PHQ-9 tool administered at least once during a 4 month period in which
	•
	there was a qualifying visit.